Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioFRA:1IJ +4.62%38 Return-on-Tangible-Asset is -53.91% as of Jun. 2026. GuruFocus rates FRA:1IJ with a GF Score™ of 38/100 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,414 Biotechnology companies, Adicet Bio ranks worse than 66.27% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Adicet Bio's annualizedNet Income for the quarter that ended in Jun. 2026 was €-74.16 Mil. Adicet Bio's average total tangible assets for the quarter that ended in Jun. 2026 was €137.56 Mil. Therefore, Adicet Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -53.91%.
The historical rank and industry rank for Adicet Bio's Return-on-Tangible-Asset or its related term are showing as below:
FRA:1IJ'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -60.84 Med: -34.49 Max: -22.13
Current: -60.84
During the past 8 years, Adicet Bio's highest Return-on-Tangible-Asset was -22.13%. The lowest was -60.84%. And the median was -34.49%.
FRA:1IJ's Return-on-Tangible-Asset is ranked worse than 66.27% of 1414
companies
in the Biotechnology industry
Industry Median: -36.16
vs FRA:1IJ: -60.84
Adicet Bio (FRA:1IJ) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Adicet Bio Return-on-Tangible-Asset Related Terms
Adicet Bio Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Adicet Bio's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1IJ vs ATRA, PYPD, GANX: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Adicet Bio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -53.91% mean?
Adicet Bio (FRA:1IJ) has a Return-on-Tangible-Asset of -53.91% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Adicet Bio and its competitors. According to the industry distribution chart, Adicet Bio ranks #937 out of 1414 companies in the Biotechnology industry, placing it in the top 66.3%.
Is Adicet Bio's Return-on-Tangible-Asset too high?
Adicet Bio's current Return-on-Tangible-Asset is -53.91%. Based on the distribution chart, Adicet Bio ranks #937 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Adicet Bio has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Return-on-Tangible-Asset compare to ATRA and PYPD?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #937 out of 1414 companies for Return-on-Tangible-Asset. This places Adicet Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Adicet Bio and its competitors. Adicet Bio's current Return-on-Tangible-Asset is -53.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Based on GuruFocus' analysis, Adicet Bio (FRA:1IJ) is currently considered Significantly Overvalued. The current Return-on-Tangible-Asset is -53.91%. Adicet Bio's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current Return-on-Tangible-Asset is -53.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
38GF Score
Get the complete analysis for FRA:1IJ
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1IJ has been successfully added to your 
